Tonix Pharmaceuticals has concluded the Phase III RESILIENT study’s clinical phase of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6mg to manage fibromyalgia.
The double-blind, placebo-controlled, registration-quality and multi-site trial has enrolled 457 patients to evaluate the safety and efficacy of TNX-102 SL in managing this condition.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
This two-arm study randomised subjects across 33 sites in the US.
The initial two weeks of treatment include a run-in period in which subjects begin on TNX-102 SL 2.8mg (one tablet) dose or placebo.
Later, all participants increased their dose to TNX-102 SL 5.6mg or two placebo tablets for the remaining 12 weeks.
Daily diary pain severity score change to week 14 from baseline for TNX-102 SL 5.6mg against placebo is the trial’s primary endpoint. It will be analysed by mixed model repeated measures with multiple imputations.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataTopline results from the trial are anticipated by the end of December.
If successful, RESILIENT is anticipated to serve as the final, well-controlled efficacy trial required for submitting a new drug application (NDA) to receive approval from the US Food and Drug Administration (FDA).
Tonix Pharmaceuticals CEO Seth Lederman said: “TNX-102 SL is a centrally-acting, non-opioid analgesic bedtime medication designed to be used on a chronic basis for the management of fibromyalgia.
“We believe TNX-102 SL works by improving sleep quality, which leads to improvement of other symptoms. In previous studies, TNX-102 SL showed broad coverage across the symptoms of fibromyalgia, including chronic widespread pain, fatigue and sleep disturbance.”
